Pharma & Industry Sponsors
Molecularly defined patients, followed over time.
OnKommon combines a living, longitudinal model of each patient with biological investigational plans in a living organism — a foundation for sponsors, CROs and diagnostics partners.
Industry · storyline
What sponsors gain from OnKommon.
01 / 06 · Defined patients
Every patient, molecularly defined.
Twin builds a structured molecular and clinical profile for each case — variants, signatures, phenotype, immune landscape and targetability, in one model.
OnKommon Twin →Continue the journey
Where to go next
Design a collaboration with OnKommon.
For pharma sponsors, CROs and diagnostics partners.